10-12 September 2018 //  Lancaster Royal Hotel, London




ERA is pleased to announce the launch of our dedicated Biomarker Division to support your development and regulatory affairs needs in this exciting field. Recognising the role and potential of biomarkers in the drug development arena, both the European regulatory authorities and the US FDA have markedly increased their visibility and activity in this space. There is clear indication, with new guidelines and procedures in place, that regulatory agencies are ready to work with those companies developing them.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad